SCYNEXIS develops antifungal drugs for hard to treat fungal infections, aimed at hospital patients and the physicians who treat them. It last closed at $2.85 on Nov 17, down 2.90% on the day.
SCYX · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 26% below its 20 day and 44% below its 50 day average. It is 89% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot at $2.83, and the nearest resistance the Pivot R1 at $2.97.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 9.2%/day
Key levels
$9.1252 week high+220.0%
$5.40200 day average+89.5%
$4.43100 day average+55.4%
$4.1150 day average+44.2%
$3.98Swing high (Oct 21)+39.6%
$3.5920 day average+26.0%
$2.97Pivot R1+4.2%
$2.85Last close
$2.83Pivot−0.7%
$2.72Pivot S1−4.6%
$2.7052 week low−5.3%
Indicators
RSI (14)
25.36
Oversold below 30
Oversold
MACD
-0.30
Below its signal line
Bearish
Stochastic
9.4
Near the bottom of its range
Oversold
ADX (14)
28.4
Trending down
Williams %R
-88.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-197.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−27.7%
Change over 10 sessions
Bearish
ATR (14)
$0.26
Typical daily range, 9.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 26.9%/day
Key levels
$9.1252 week high+220.0%
$5.40200 day average+89.5%
$4.43100 day average+55.4%
$4.1150 day average+44.2%
$3.98Swing high (Oct 21)+39.6%
$3.5920 day average+26.0%
$2.97Pivot R1+4.2%
$2.85Last close
$2.83Pivot−0.7%
$2.72Pivot S1−4.6%
$2.7052 week low−5.3%
Indicators
RSI (14)
33.02
Weak, oversold below 30
Neutral
MACD
-0.61
Below its signal line
Bearish
Stochastic
5.3
Near the bottom of its range
Oversold
ADX (14)
12.8
No clear trend
Williams %R
-95.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-178.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−41.1%
Change over 10 sessions
Bearish
ATR (14)
$0.77
Typical daily range, 26.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SCYX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how SCYX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow SCYX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SCYX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SCYX is in one of them and how their past SCYX trades turned out.
SCYNEXIS is a pharmaceutical company based in Jersey City, New Jersey, that develops antifungal medicines. Its approved product, BREXAFEMME, treats vaginal yeast infections, and it has been licensed to GSK. Its main development candidate, SCY-247, is an oral and intravenous antifungal being studied for serious fungal infections, mainly in hospital patients with weakened immune systems and in other patients at high risk. The company's customers are mainly physicians at major medical centers who treat these patients.